Decision and cost-utility analyses considered the tradeoffs of treating patent ductus arteriosus (PDA) using conventional surgery versus transcatheter implantation of the Rashkind occluder. Physicians and informed lay parents assigned utility scores to procedure success/complications combinations seen in prognostically similar pediatric patients with isolated PDA treated from 1982 to 1987. Utility scores multiplied by outcome frequencies from a comparative study generated expected utility values for the two approaches. Cost-utility analyses combined these results with simulated provider cost estimates from 1989. On a 0-100 scale (worst to best observed outcome), the median expected utility for surgery was 99.96, versus 98.88 for the occluder. Results of most sensitivity analyses also slightly favored surgery. Expected utility differences based on 1987 data were minimal. With a mean overall simulated cost of $8,838 vs $12,466 for the occluder, surgery was favored in most cost-utility analyses. Use of the inherently less invasive but less successful, more risky, and more costly occluder approach conferred no apparent net advantage in this study. Analyses of comparable current data would be informative.
MavroudisCBackerCLGevitzM.Forty-six years of patent ductus arteriosus division at Children’ Memorial Hospital of Chicago. Standards for comparison [review]. Ann Surg1994;220: 402–9.
3.
RashkindWJCuasoCC.Transcatheter closure of patent ductus arteriosus. Pediatr Cardiol1979;1: 3–7.
4.
RashkindWJMullinsCEHellenbrandWETaitMA.Nonsurgical closure of patent ductus arteriosus. Circulation1987;75: 583–9.
5.
LatsonLAHofshirePJKuglerJDCheathamJPGumbinerCHDanforthDA.Transcatheter closure of patent ductus arteriosus in pediatric patients. J Pediatr1989;115: 549–53.
6.
LloydTRFedderlyRMendelsohnAMSandhuSKBeekmanRHIIITranscatheter occlusion of patent ductus arteriosus with Gianturco coils. Circulation1993;88(part 1):1412–20.
7.
DyckJDBensonLNSmallhornJFMcLaughlinPRFreedomRMRoweRD.Catheter occlusion of the persistently patent ductus arteriosus. Am J Cardiol1988;62: 1089–92.
8.
HoskingMCBensonLNMuseweNNDyckJDFreedomRM.Transcatheter occlusion of the persistently patent ductus arteriosus occluder: Forty-month follow-up and prevalence of residual shunting. Circulation1991;84: 2313–7.
9.
Report of the European Registry.Transcatheter occlusion of persistent arterial duct. Lancet. 1992;340: 2062–6.
10.
Ali-KhanMAAI-YousefJMullinsCESawyerW.Experience with 205 procedures of transcatheter closure of ductus arteriosus in 182 patients, with special reference to residual shunts and long-term follow-up. J Thorac Cardiovasc Surg1992;104: 1721–7.
11.
KassirerJP.The principles of clinical decision making: An introduction to decision analysis. Yale J Biol Med1976;49: 149–64.
12.
WeinsteinMCFinebergHVElsteinAS (eds). Clinical Decision Analysis. Philadelphia, PA: W. B. Saunders, 1980.
DrummondMFStoddartGLTorranceGW.Cost-utility analysis. In: Methods for the Economic Evaluation of Health Care Programmes. Oxford, U.K.: Oxford Medical Publications, 1987;112–48.
15.
GrayDTFylerDCWalkerAMWeinsteinMCChalmersTC.Clinical outcomes and costs of transcatheter as compared with surgical closure of patent ductus arteriosus. N Engl J Med1993;329: 1517–23.
16.
FinklerS.The distinction between cost and charges. Ann Intern Med1982;96: 102–9.
GrayDT.Cost effectiveness analysis of interventions for congenital heart disease. J Interven Cardiol1995;8: 1–19.
19.
GrayDT.The application of epidemiologic methods to the assessment of outcomes in interventional cardiology. J Interven Cardiol1997;10: 41–50.
20.
ReadJLQuinnRJBerwickDMFinebergHVWeinsteinMC.Preferences for health outcomes. Comparison of assessment methods. Med Decis Making1984;4: 315–29.
21.
GrayDTWalkerAMFylerDCChalmersTC.Examination of the early ‘learning curve’ for transcatheter closure of patent ductus arteriosus using the Rashkind occluder. Circulation. 1994;90[part 2):II-36–II-42.
22.
HollenbergJ. SMLTREE Version 2.2 (Decision Analysis Software). Roslyn, NY, 1987.
23.
DoubiletPBeggCBWeinsteinMCBraunPMcNeilBJ.Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making1985;5: 157–77.
24.
LaupacisAFeenyDDetskyASTugwellPX.How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J1992;146: 473–81.
25.
GehanEFreireichE.Non-randomized controls in cancer clinical trials. N Engl J Med1974;290: 198–203.
26.
SackettDL.Bias in analytic research. J Chronic Dis1979;32: 51–63.
27.
HlatkyMCaliffRMHarrellFEJr.LeeKLMarkDBPryorDB.Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. J Am Coll Cardiol1988;11: 237–45.
28.
GreenlandSNeutraR.Control of confounding in the assessment of medical technology. Int J Epidemiol1980;9: 361–7.
29.
MiettinenO.The need for randomization in the study on intended effects. Stat Med1983;2: 267–71.
30.
ParducciA.Contextual effects: A range frequency analysis. In: CarteretteEFriedmanM (eds). Handbook of Perception. New York: Academic Press, 1974.
31.
Llewellyn-ThomasHSutherlandHJTibshiraniRFCiampiATillJEBoydNF.The measurement of patients’ values in medicine. Med Decis Making1982;2: 449–62.
32.
KeeneyRLRaiffaH.Decisions with Multiple Objectives: Preferences and Value Tradeoffs. New York: Wiley, 1976.
33.
TorranceGW.Utility approach to measuring health-related quality of life. J Chronic Dis1987;40: 593–600.
34.
KrischerJ.Utility structure of a medical decision-making problem. Oper Res1977;24: 951–72.
35.
TorranceGWBoyleMHHorwoodSP.Application of multi-attribute utility theory to measure social preferences for health states. Oper Res1982;30: 1043–69.
36.
BoyleMTorranceGWSinclairJCHorwoodSP.Economic evaluation of neonatal intensive care of very low birth-weight infants. N Engl J Med1983;308: 1330–7.
37.
FeenyDFurlongWBarrRDTorranceGWRosenboumPWaltzmanS.A comprehensive multi-attribute system for classifying the health status of survivors of childhood cancer. J Clin Oncol1992;10: 923–8.
38.
HolmesMMRovnerDRRothertMLWomen's and physicians’ utilities for health outcomes in estrogen replacement therapy. J Gen Intern Med1987;2: 178–82.
39.
SchmittNGogateJRothertMCapturing and clustering women's judgment policies: The case of hormonal therapy for menopause. J Gerontol1991;46: 92–101.
40.
HolzmanGBRavitchMMMethenyWRothertMLHolmesMHoppeRB.Physicians’ judgments about estrogen replacement therapy for menopausal women. Obstet Gynecol1984;63: 303–11.
41.
ElsteinASHolzmanGBRavitchMMComparison of physicians’ decisions regarding estrogen replacement therapy for menopausal women and decisions derived from a decision analytic model. Am J Med1986;80: 246–58.
42.
Llewellyn-ThomasHASutherlandZHJTheilEC.Do patients’ evaluations of a future health state change when they actually enter that state?Med Care1993;31: 1002–12.
43.
McNeilBJPaukerSGSoxHCJr.TverskyA.On the elicitation of preferences for alternative therapies. N Engl J Med1982;306: 1259–62.
44.
FlemingWHSarafianLBKuglerJDNelsonRMJr.Ligation of parent ductus arteriosus in premature infants: Importance of accurate anatomic definition. Pediatrics1983;71: 373–5.
45.
JonesJ.Twenty-five years’ experience with the surgery of patent ductus arteriosus. J Thorac Cardiovasc Surg1965;50: 149–68.
46.
GhaniSAHashimR.Surgical management of patent ductus arteriosus. A review of 413 cases. J R Coll Surg Edinburgh1989;34: 33–6.
47.
PowellCBMollerJH.Outcomes research using a voluntary generic registry. Progr Pediatr Cardiol1997;7: 87–90.
48.
GrayDHewittPChalmersT.The evaluation of surgical therapy. In: RutkowI (ed). The Socioeconomics of Surgical Health Care Delivery. St. Louis, MO: C. V. Mosby, 1989;228–56.
49.
PagottoLTMullinsCEHellenbrandWELatsonLACheathamJP.Cost comparative study of surgical vs transcatheter closure of isolated patent ductus arteriosus (abstr). Circulation1994;90: I-642.
50.
HumanDGMcIntyreLGniewekAHannaBD.Technology assessment of nonsurgical closure of patent ductus arteriosus: An evaluation of the clinical effectiveness and costs of a new medical device. Pediatrics1995;96: 703–6.
51.
Food and Drug Administration, HHS.Medical devices; investigational devices; interagency agreement between the Food and Drug Administration and the Health Care Financing Administration; categorization of investigational devices for coverage under Medicare; availability. Fed Reg.1996;61(37): 7011–2.
52.
WoodsJRSaywellRMNyhuisAWThe learning curve and the cost of heart transplantation. Health Serv Res1992;27: 219–38.
53.
KarwandeSVRowlesJR.Simplified muscle-sparing thoracotomy for patent ductus arteriosus ligation in neonates. Ann Thorac Surg1992;54: 164–5.
54.
RaoPSSiderisEBHaddadJTranscatheter occlusion of patent ductus arteriosus with adjustable buttoned device. Initial closure experience. Circulation1993;88: 1119–26.
55.
BridgesNDPerrySBParnessIKeaneJFLockJE.Transcatheter closure of a large patent ductus arteriosus with the clamshell septal umbrella. J Am Coll Cardiol1991;18: 1297–302.
56.
LabordeFNoirhommePKaramJBatisseABourelPMauriceOS.A new video-assisted thoracoscopic surgical technique for interruption of patent ductus arteriosus in infants and children. J Thorac Cardiovasc Surg1993;105: 278–80.
57.
BurkeRPWernovskyGVan Der VeldeMHansenDCastanedaAR.Video-assisted thoracoscopic surgery for congenital heart disease. J Thorac Cardiovasc Surg1995;109: 499–508.
